AMPH241220P70000
- 0.00
- 0.000.00%
Amphastar Pharmaceuticals Newsroom
US Manufacturing Index Rises To 43, Highest Since 2020
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference
Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors
Amphastar Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Amphastar Pharma Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 Financial Results.
Piper Sandler Maintains Amphastar Pharmaceuticals(AMPH.US) With Buy Rating, Maintains Target Price $66
Needham Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating
Amphastar Pharmaceuticals Inc. (AMPH) Q3 2024 Earnings Call Transcript Summary
Amphastar Pharmaceuticals Non-GAAP EPS of $0.96 Misses by $0.02, Revenue of $191.2M Misses by $3.49M
Amphastar Pharmaceuticals Expands Share Buyback Program By $50M To Offset Equity Compensation Dilution, With No Set End Date
Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Posts Q3 EPS $0.96
Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Reports Q3 Revenue $191.2M
Express News | Amphastar Pharmaceuticals Q3 Adjusted EPS USD 0.96 Vs. IBES Estimate USD 0.99
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2024
Here Are the Major Earnings After the Close Today
Earnings Preview: AMPH to Report Financial Results Post-market on November 06
$Amphastar Pharmaceuticals(AMPH.US)$ is scheduled to release its financial results post-market on November 06 ET. Earnings PreviewAnalysts estimate $Amphastar Pharmaceuticals(AMPH.US)$ to post
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6, 2024
Capital One Financial Maintains Amphastar Pharmaceuticals(AMPH.US) With Buy Rating, Maintains Target Price $70
Amphastar Pharmaceuticals: Strong Product Pipeline and Financial Position Justify Buy Rating
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Stock Is Going Strong: Is the Market Following Fundamentals?